In NSCLC lines, the combination of XPO1i together with AKTi and SRCi, which reactivate the RhoGAP and tumor suppressor activities of DLC1 (ref. 28), potently inhibited tumor growth. The gene discussed is DLC1; the disease is non-small cell lung carcinoma.